
Cardiac Arrest Survival Rises Over Last Two Decades
While the incidence of cardiac arrest occurring outside the hospital has remained relatively stable, at about 81 per 100,000 person-years, between 2001 and 2020, data show survival rates improved from 14.7% to 18.9% during that period. This improvement corresponded with increased bystander cardiopulmonary resuscitation (CPR), from 55.5% to 73.9%, and the use of early automated external defibrillators, from 2.2% to 10.9%.
METHODOLOGY:
Researchers conducted a retrospective cohort analysis of 25,118 adults in King County, Washington, who had experienced an out-of-hospital cardiac arrest (OHCA) treated by emergency medical services (EMS) between 2001 and 2020.
Of those, 15,994 (63.7%) were men and 9124 were women; the median age was 65 years.
Annual incidence calculations were stratified by sex, age group (less than 65 years and 65 years or older), and initial rhythm (shockable, nonshockable).
The tesearchers evaluated temporal trends using Poisson regression for incidence and survival to hospital discharge, with resuscitation assessed in five-year groups.
TAKEAWAY:
Overall survival to hospital discharge improved significantly over time: 14.7% (859 of 5847 individuals) in 2001-2005, 17.4% (1024 of 5885 individuals) in 2006-2010, 19.3% (1232 of 6376 individuals) in 2011-2015, and 18.9% (1322 of 7010 individuals) in 2016-2020 (P < .001 for trend).
Survival rates increased substantially for shockable OHCA, from 35% to 47.5%, and for nonshockable OHCA, from 6.4% to 10.1% between the periods spanning 2001-2005 and 2016-2020 (P < .001 for trend).
Improvements were observed in both prehospital resuscitation (survival to hospital admission) and in-hospital survival (P < .001 for trend).
Community response rose significantly, with bystander CPR increasing from 55.5% to 73.9% and early use of an automated external defibrillator rising from 2.2% to 10.9% (P < .001 for trend).
IN PRACTICE:
'Resuscitation outcomes improved over time, a temporal trend that was evident overall and when stratified by presenting arrest rhythm,' the researchers reported. 'The outcome improvements corresponded to improvements in health services such as increase in bystander CPR, AED application before EMS among patients with shockable rhythm, and hospital-based care with targeted temperature management and coronary intervention. The results demonstrate the dynamic nature of OHCA incidence and resuscitation care and outcome that collectively help provide a foundational context to consider strategies of prevention and treatment.'
SOURCE:
The study was led by Owen McBride, MD, of the Department of Emergency Medicine at the University of Washington in Seattle. It was published online July 16 in JAMA Cardiology.
LIMITATIONS:
According to the authors, while the study represents a singular regional experience that could affect generalizability, as OHCA incidence and outcome can vary based on geography. Some people who experience OHCA have an emergency response but do not receive resuscitation attempts due to signs of irreversible death or do-not-resuscitate orders, whereas some OHCA events do not receive a 911 medical response.
DISCLOSURES:
Michael Sayre, MD, reported receiving personal fees from Styker Emergency Response outside the submitted work. Thomas Rea, MD, MPH, reported receiving grants from Philips Medical Funding and the American Heart Association for research independent of the current publication. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed company, reported its Phase 2b trial of inidascamine for cognitive impairment linked to schizophrenia missed its primary endpoint. Warning! GuruFocus has detected 6 Warning Signs with ATAI. The oral compound, engineered to modulate multiple neurotransmitter pathways for pro?cognitive effects, failed to outperform placebo on key cognitive measures. Recognify said the results fell short of statistical significance. Atai's CEO acknowledged the setback but highlighted inidascamine's potential in CIAS and other indications. He added that Atai will redirect its efforts toward its wholly?owned psychedelic programs focused on affective disorders. Investors have been closely watching Atai's broader pipeline, which includes compounds targeting depression, PTSD and Alzheimer's disease. This latest trial disappointment adds to a string of mid?stage readouts that have tested market sentiment around biotech firms pivoting to next?generation neuroscience therapies. Despite today's drop, Atai's management reiterated its commitment to advancing its lead psychedelic candidates through upcoming Phase 1 and Phase 2 trials. Based on the one year price targets offered by 6 analysts, the average target price for ATAI Life Sciences NV is $9.83 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies a upside of +175.44% from the current price of $3.57. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Parents call on FDA for path forward after Duchenne's gene therapy pause
The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient receiving treatment for muscular dystrophy. Alison and William Small are urging the agency to restore access to the drug, the only FDA-approved treatment for Duchenne's muscular dystrophy. Speaking to 'Morning in America,' the Smalls call for transparency and a clear path forward from federal regulators. They say families affected by Duchenne's deserve to understand the risks and that many believe the treatment is worth fighting for. Solve the daily Crossword


Forbes
6 minutes ago
- Forbes
OpenEvidence's Meteoric Rise Is Huge For Doctors
Medical research and science has never been easier to access. OpenEvidence has raised hundreds of millions of dollars. In its most recent funding round, it raised a $210 million Series B from prominent investors such as Google Ventures and Kleiner Perkins, bringing the company's valuation to nearly $3.5 billion. The company's goal is straightforward and incredibly ambitious: to collate the entire corpus of medical knowledge and research developments in a way that is easily accessible to physicians and thereby, improve health outcomes. The service is aiming to provide a similar 'touch and feel' as other generative AI services such as Chat GPT or Google's Gemini—except, its target audience is primarily doctors. Medical science is a rapidly evolving field with a perpetually expanding sea of knowledge, especially as research and development across the fields of disease, therapeutics and human sciences continue to grow. In fact, as Sequoia Capital notes, 'a new PubMed article [which is often the flagship resource for peer-reviewed science studies]The value of this type of technology is increasingly being recognized. The latest models for OpenAI's ChatGPT (GPT 4.1 and o3) have displayed incredible efficacy in taking command of medical knowledge; in May, the company published its work with HealthBench, proposing a rubric for model performance in healthcare and also indicating that GPT's latest models performed at par or even better than standard physician evaluations. Even Google's Gemini family of models has made significant progress in this space; its MedLM suite, for example, is a highly tuned model that can aid the entire healthcare workflow, ranging from answering medical questions to deciphering unstructured health data. Why is all of this important? There are a few different reasons. First and foremost, this technology is aiming to democratize medical knowledge in a way that is easy to access. Furthermore, it comes at a time when the healthcare system, and its respective workforce, is facing unprecedented headwinds. Studies have repeatedly indicated that physician burnout and attrition are incredibly concerning problems for health systems and organizations of all sizes; physicians simply do not have the bandwidth to fulfill all of their patient care duties in addition to the increasingly prevalent administrative, compliance and regulatory burdens placed on them. This also means that there is less time for professional development and continuing education. These technologies can serve as a major advantage to the physician workflow as they provide an opportunity to easily query, fact-check and understand the latest science that is involved with a condition. Carry this even further with tools such as OpenEvidence DeepConsult, which gives physicians access to PhD-level AI agents that can conduct medical research, or Gemini's foundation models that can rapidly decipher medical images, or even AI scribing technology that can rapidly generate patient-physician encounter notes, and soon, hours can be saved from a physician's daily workflow. This translates not only to millions of dollars saved annually in system costs, but also to more time available to spend with patients, improved access to care, and ultimately, increased efficacy and quality of care provided.